B-cell chronic lymphocytic leukemia risk in association with serum

[Guest guest]

BlankB-cell chronic lymphocytic leukemia risk in association with serum leptin

and adiponectin: a case-control study in Greece.

M Dalamaga, BH Crotty, J Fargnoli, E Papadavid, A Lekka, M Triantafilli, K

Karmaniolas, I Migdalis, A Dionyssiou-Asteriou, and CS Mantzoros

Cancer Causes Control, May 8, 2010; .

Department of Clinical Biochemistry, Medical School, University of Athens,

" Attikon " General University Hospital, 1 Rimini Street, Chaidari, 12462, Athens,

Greece.

AIM: Leptin and adiponectin are two well-studied adipokines in relation to

malignancies. In this study, we examined the association between

leptin/adiponectin and risk of B-cell chronic lymphocytic leukemia (B-CLL), as

well as the relationships between adipokines and several established prognostic

factors of B-CLL. METHODS: Ninety-five patients with incident B-CLL and 95

hospital controls matched on age and gender were studied between 2001 and 2007,

and blood samples were collected. Leptin, total and high molecular weight

adiponectin, and prognostic markers of B-CLL were determined. RESULTS: Cases had

a higher body mass index (BMI) than controls (p = 0.01) and lower levels of

leptin (p < 0.01). Significantly more cases than controls presented a family

history of lymphohematopoietic cancer (LHC) (p = 0.01). Higher serum leptin

levels were associated with lower risk of B-CLL adjusting for age, gender,

family history of LHC, BMI and serum adiponectin; the multivariate odds ratio

comparing highest to lowest tertile was 0.05 (95% CI 0.01-0.29, p trend <

0.001); Adiponectin was not significantly different between cases and controls.

CONCLUSION: Leptin was found to be inversely associated with risk of CLL but in

contrast to prior studies of CLL and hematologic malignancies, this study found

no significant association between CLL and adiponectin.

PMID: 20454844